May 2014 issue
Click the above link to access the complete Digital Edition of the May 2014 issue of MM&M, with all text, charts and pictures.
When it comes to the patent cliff, pharma, it seems, is so over it
Patent expiries took their toll but wore off quickly last year, helping nudge growth in prescription drug spend back into positive territory. Marc Iskowitz reports
Co-pay programs have long divided opinion among stakeholders. Sarah Morgan reports on the findings of three new exclusive mini-surveys of key stakeholders, including suggestions on ...
Why do some brands flop and others finish first? It could come down to health literacy. But doing it right involves more than just choosing ...
Few autoimmune competitors even come close to commercial stalwarts Humira, Enbrel and Remicade. But as a host of high-science treatments emerge seeking to threaten their ...
An esteemed panel of marketers from small biotech companies discusses the unique challenges and opportunities of bringing novel products to market. James Chase moderates the ...
The 2014 juding panel for the MM&M Awards is a group of esteemed leaders, thinkers and experts who represent a wide range of disciplines within ...
Kimberly Ray, VP, integrated site services, Quintiles
Every now and then a new drug comes out that dramatically changes the trajectory of a killer disease. Such a drug is Sovaldi, the new ...
Are the Ranbaxy Laboratories and Sun Pharmaceutical recalls of prescription generics isolated incidents, or signs of a pharma culture in which corners are too often ...
The company unveiled the mix-and-match marketing management tool at the Eye for Pharma conference in Barcelona.
Private Japanese company Kowa is bolstering Amarin's sales force by 250
News on PM Live, Teva and the Wall Street Journal
Firms are gearing up for the detailed filing of Sunshine data later this year, after which the inquiries and disputes window will begin.
Bayer HealthCare launched an educational website for US physicians about the rare, life-threatening condition chronic thromboembolic pulmonary hypertension (CTEPH).
News on HHS, ACCME, Haymarket Medical Education and Smith & Nephew
Medscape's survey of over 24,000 physicians found that a paycheck is not necessarily linked to a physician's professional satisfaction.
Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.
News on BMJ, MedPage Today and John Wiley & Sons
As brand communications responsibilities shift from local markets to centralized hubs, what will happen to the smaller, local agencies, and what will regionalization mean in ...
A study by consulting firm Accenture shows that patients not only expect digital outreach, but that their desire to be engaged is consistently being ignored.
Praised for helping navigate the shift by advertisers into digital, media vet Kim Kadlec is leaving pharma for a new role at AOL.
News on Tufts University Center for the Study of Drug Development, Mayo Clinic and Healthcare.gov
AbbVie's "Perspectives—Art, Inflammation and Me," an exhibit centered around inflammatory diseases, looks to offer patient perspective through an artistic medium.
GlaxoSmithKline claims that Sandoz needs to change the packaging for its generic Advair.
Kudos to Astellas and its Myrbetriq brand for a DTC campaign that pulls all of DTC's levers.
Should pharma formulate a super matrix to determine the FMV of research incentives?
The Affordable Care Act has spurred double-digit increases in demand for pharmaceuticals, new data suggest.
IMS Health raised $1.3 billion last month in its New York IPO.
CDM, the Omnicom network of healthcare agencies, named Josh Prince, previously the group's chief creative officer, to president. He replaces Carol DiSanto.
Precision for Medicine has acquired Hobart Group Holdings, which specializes in strategic communications that address payer needs.
Newson ID Media, Frontline Medical Communications and ContextMedia
FDA has insisted that its antique regulations can address every new promotional challenge
Former Speaker of the House and presidential candidate Newt Gingrich has declared that it's time to replace FDA
Specialty brands ignore more than 50% of the specialists they serve, so 50% of the audience is wide open
You have to approach quality assurance as an intrinsic part of the process, not an afterthought
How can testimonials make their mark in a branded space? By getting real.
Pam Hamlin, Global president, Arnold Worldwide
Jen Jonsson, Director, Operations, Cambridge BioMarketing
Promotions and hires for manufacturers and agencies
A general consensus is that a "shake-up" of some kind is coming
*Group discounts available on request
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.